Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
micafungin + amphotericin B + itraconazole
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination antifungal therapy consisting of micafungin (an echinocandin), amphotericin B (a polyene), and itraconazole (a triazole). Micafungin inhibits the synthesis of (1,3)-beta-D-glucan, an essential component of fungal cell walls. Amphotericin B binds to ergosterol in fungal cell membranes, creating pores that lead to cell death. Itraconazole inhibits fungal cytochrome P450-dependent enzymes, preventing the synthesis of ergosterol. This combination has been studied for treating acute invasive aspergillosis, with micafungin showing potential synergistic activity with amphotericin B.
02
Targets
Beyond the preview
Go deeper on micafungin + amphotericin B + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on micafungin + amphotericin B + itraconazole.